Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018
- PMID: 34162011
- DOI: 10.1111/apt.16448
Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018
Abstract
Background: Data about thiopurines or anti-TNF use during pregnancy in women with inflammatory bowel diseases (IBD) are reassuring. However, many studies are based upon small sample sizes.
Aims: To assess IBD medication safety during pregnancy.
Methods: Using the French national health database, which covers more than 99% of the French population, around 65 000 000 people, we identified pregnancies ending with a birth in IBD patients in France between 2010 and 2018. Pregnancy outcomes (vital status at birth, birth term, and weight for gestational age) were compared according to treatment exposure during pregnancy using propensity score-weighted marginal logistic regression models.
Results: 27 729 pregnancies were included: 3554 were exposed to thiopurines monotherapy, 3525 to anti-TNF monotherapy, 839 to combination therapy, and 19 811 unexposed. Pregnancies exposed to thiopurines monotherapy compared to unexposed pregnancies more frequently resulted in stillbirths (1.0% vs 0.5%, aOR 2.04; 95%CI: 1.18-3.55), preterm birth (12.3% vs 7.1%, aOR 1.76; 95%CI: 1.55-2.00), large for gestational age (10.6% vs 8.4%, aOR 1.32; 95%CI: 1.13-1.53) and less frequently in small for gestational age (9.6% vs 11.1%, aOR 0.79; 95%CI: 0.67-0.92). By contrast, pregnancies exposed to anti-TNF monotherapy were not different from unexposed pregnancies as regards to these outcomes. Compared to unexposed pregnancies, those exposed to combination therapy more frequently resulted in preterm births (aOR 1.55; 95%CI: 1.15-2.11) and larger for gestational age (aOR 1.61; 95%CI: 1.13-2.29) but did not differ as regards to stillbirths.
Conclusions: Pregnancies exposed to thiopurines more frequently resulted in stillbirths, preterm births and large for gestational age compared to pregnancies exposed to anti-TNF or unexposed pregnancies. By contrast, pregnancies exposed to anti-TNF monotherapy were not associated with these outcomes.
© 2021 John Wiley & Sons Ltd.
Comment in
-
Editorial: thiopurines but not anti-TNF monotherapy are linked to worse pregnancy outcomes in a large population-based study.Aliment Pharmacol Ther. 2021 Aug;54(3):343-344. doi: 10.1111/apt.16472. Aliment Pharmacol Ther. 2021. PMID: 34236094 No abstract available.
Similar articles
-
Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018.Aliment Pharmacol Ther. 2020 Nov;52(9):1480-1490. doi: 10.1111/apt.16074. Epub 2020 Sep 10. Aliment Pharmacol Ther. 2020. PMID: 33095502
-
Serious Infections in Children Born to Mothers With Inflammatory Bowel Disease With In Utero Exposure to Thiopurines and Anti-Tumor Necrosis Factor.Clin Gastroenterol Hepatol. 2022 Jun;20(6):1269-1281.e9. doi: 10.1016/j.cgh.2021.07.028. Epub 2021 Jul 21. Clin Gastroenterol Hepatol. 2022. PMID: 34298191
-
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.JAMA. 2017 Nov 7;318(17):1679-1686. doi: 10.1001/jama.2017.16071. JAMA. 2017. PMID: 29114832 Free PMC article.
-
Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2020 Oct;52(8):1289-1297. doi: 10.1111/apt.16050. Epub 2020 Aug 25. Aliment Pharmacol Ther. 2020. PMID: 32840893
-
Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.Hum Exp Toxicol. 2015 May;34(5):445-59. doi: 10.1177/0960327114550882. Epub 2014 Nov 5. Hum Exp Toxicol. 2015. PMID: 25378092
Cited by
-
Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Epub 2023 Sep 7. J Neurol. 2024. PMID: 37676297 Free PMC article. Review.
-
Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.Dig Dis Sci. 2023 Sep;68(9):3557-3561. doi: 10.1007/s10620-023-08016-x. Epub 2023 Jul 5. Dig Dis Sci. 2023. PMID: 37402980
-
Histological remission in inflammatory bowel disease and risk of adverse pregnancy outcomes: A nationwide study.EClinicalMedicine. 2022 Nov 7;53:101722. doi: 10.1016/j.eclinm.2022.101722. eCollection 2022 Nov. EClinicalMedicine. 2022. PMID: 36467453 Free PMC article.
-
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy.Saudi J Gastroenterol. 2023 Dec 15;30(4):181-97. doi: 10.4103/sjg.sjg_318_23. Online ahead of print. Saudi J Gastroenterol. 2023. PMID: 38099556 Free PMC article.
-
Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.Int Arch Allergy Immunol. 2025;186(6):579-593. doi: 10.1159/000542217. Epub 2024 Dec 3. Int Arch Allergy Immunol. 2025. PMID: 39626647 Free PMC article.
References
REFERENCES
-
- Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150:734-757.e1.
-
- Meyer A, Drouin J, Weill A, et al. Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018. Aliment Pharmacol Ther. 2020;52:1480-1490.
-
- Kirchgesner J, Lemaitre M, Rudnichi A, et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014. Aliment Pharmacol Ther. 2017;45:37-49.
-
- Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20:36-46.
-
- Chapman TP, Gomes CF, Louis E, et al. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5:63-79.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources